{"id":"W4403868539","doi":"10.3389/fonc.2024.1376551","title":"First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Mersana Therapeutics; EMD Serono; SK Life Science; Pfizer; Merck KGaA; Genentech; Les Laboratories Pierre Fabre; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Aptitude Health","keywords":"Medicine; Nausea; Combination therapy; Adverse effect; Internal medicine; Pharmacokinetics; Antibody; Pharmacology; Anemia; Monoclonal antibody; Oncology; Gastroenterology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00250128,0.001809683,0.001735396,0.0004799162,0.0003711947,0.000974695,0.0007698001,0.0009692435,0.00314293],"category_scores_gemma":[0.001105842,0.0005428737,0.0014663,0.0003958528,0.0006430069,0.0008504449,0.0004377317,0.004213807,0.0006706959],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001724603,"about_ca_system_score_gemma":0.001544678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009327987,"about_ca_topic_score_gemma":0.002289438,"domain_scores_codex":[0.9992722,0.0003077205,0.00003989226,0.000110829,0.00008997991,0.0001794548],"domain_scores_gemma":[0.999161,0.0001440809,0.0002127153,0.00009400114,0.00007769319,0.0003105843],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4370484,0.1564477,0.01309183,0.001381717,0.002477868,0.0004288115,0.001061658,0.01290635,0.1497456,0.0006617642,0.01760969,0.2071387],"study_design_scores_gemma":[0.269623,0.6626173,0.02973757,0.00008156987,0.0009111904,0.00060212,0.0001090594,0.004239798,0.02306332,0.0004679893,0.008472163,0.000074945],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903958,0.002310966,0.001232024,0.0004231311,0.00007412869,0.00231107,0.001544176,0.0001387291,0.001570061],"genre_scores_gemma":[0.9863071,0.001395438,0.003521259,0.0008697709,0.00007180149,0.002028781,0.003558758,0.00006490307,0.002182121],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00314293,"threshold_uncertainty_score":0.01322818,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007030517645121834,"score_gpt":0.3112422976780342,"score_spread":0.3042117800329123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}